<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624077</url>
  </required_header>
  <id_info>
    <org_study_id>NJLT001</org_study_id>
    <nct_id>NCT01624077</nct_id>
  </id_info>
  <brief_title>Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance</brief_title>
  <acronym>Treg</acronym>
  <official_title>Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Promote Donor-specific Clinical Liver Transplantation Tolerance in Nanjing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs&#xD;
      from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs&#xD;
      (1 x 106 cells/kg) at several intervals (for graft specific tolerance induction).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first trial will involve the generation of CD4+CD25+CD127- Tregs from peripheral blood of&#xD;
      pre-transplant patients, followed by a course (up to 24 months) of tacrolimus (5-10 ng/ml)&#xD;
      treatment (to prevent chronic rejection) and the administration of the CD4+CD25+CD127- Tregs&#xD;
      (1 x 106 cells/kg) at several intervals (for tolerance induction). The immunesuppress drugs&#xD;
      will be gradully withdraw within one year. The number of CD4+CD25+ Tregs needed is based on&#xD;
      the assumption that the frequencies of alloreactive CD4+ T cells with direct and indirect&#xD;
      allospecificity were 1/104 and 1/105, respectively.&#xD;
&#xD;
      The second trial will be carried out in 1-10 year post living donor liver transplantation&#xD;
      patients currently under immunosuppressive drug treatment. The investigators will isolate&#xD;
      CD4+CD25+CD127- Tregs from these patients, and expand them with mismatched living donor&#xD;
      antigens. The patients will be subsequently treated with the expanded donor-antigen specific&#xD;
      CD4+CD25+CD127- Tregs (1 x 106 cells/kg) at several intervals, and immunosuppressive drug&#xD;
      treatment will be withdrawn.&#xD;
&#xD;
      In both clinical trials, the investigators will monitor the number of allospecific Tregs in&#xD;
      patients at different time periods, and to test their suppressive functions in vitro. If&#xD;
      there will be any signs of graft rejection, patients will be switched back to&#xD;
      immunosuppressive drug treatment. The investigators expect that the innovative Tregs&#xD;
      immunosuppressive regimen will lead to achieve permanent liver transplantation tolerance&#xD;
      without the use of conventional immunosuppressive drugs: the holygrail in clinical&#xD;
      transplantation medicine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>one year posttransplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>3 years post transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of biopsy-proven acute or chronic organ rejection</measure>
    <time_frame>3 years post transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events associated with liver transplantation and immunosuppression</measure>
    <time_frame>3 years posttransplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Chronic Rejection of Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Regulatory T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Regulatory T cells</intervention_name>
    <description>Tregs will inject after liver transplantation</description>
    <arm_group_label>Regulatory T cells</arm_group_label>
    <other_name>Treg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight greater than 50kg&#xD;
&#xD;
          -  Will be receiving a living-related primary liver allograft&#xD;
&#xD;
          -  Negative B-cell and T-cell cytotoxic and flow cytometry crossmatch&#xD;
&#xD;
          -  Normal echocardiogram (ECG) with an ejection fraction of greater than 50%&#xD;
&#xD;
          -  Parents willing to comply with the study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current active infection&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Evidence of HIV infection or known HIV positive serology&#xD;
&#xD;
          -  Antibody positive for hepatitis C virus&#xD;
&#xD;
          -  Surface antigen positive for HBV&#xD;
&#xD;
          -  Recipient or donor is positive for tuberculosis (TB), under treatment for suspected&#xD;
             TB, or previously exposed to TB (positive Mantoux test)&#xD;
&#xD;
          -  Current cancer or a history of cancer&#xD;
&#xD;
          -  Uncontrolled concomitant infections, severe diarrhea, vomiting, active upper&#xD;
             gastrointestinal tract malabsorption, active peptic ulcer, or any other unstable&#xD;
             medical condition that could interfere with this study&#xD;
&#xD;
          -  Currently receiving an investigational drug or received an investigational drug within&#xD;
             30 days prior to transplant&#xD;
&#xD;
          -  Currently receiving any immunosuppressive agent&#xD;
&#xD;
          -  Anticipated contraindication to taking medications orally or via nasogastric tube by&#xD;
             the morning of Day 2 following completion of the transplant procedure&#xD;
&#xD;
          -  Require certain medications&#xD;
&#xD;
          -  Known hypersensitivity to any of the study medications,&#xD;
&#xD;
          -  Any form of substance abuse, psychiatric disorder, or other condition that, in opinion&#xD;
             of the investigator, may interfere with the study&#xD;
&#xD;
          -  Anticipated contraindication to study medications administration for longer than 5&#xD;
             days post-transplant&#xD;
&#xD;
          -  History of rejection after organ transplantation&#xD;
&#xD;
          -  Muti-organ transplantation&#xD;
&#xD;
          -  Autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>February 21, 2015</last_update_submitted>
  <last_update_submitted_qc>February 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Ling Lu</investigator_full_name>
    <investigator_title>Liver transplantation Center</investigator_title>
  </responsible_party>
  <keyword>Regulatory T cells</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Rejection</keyword>
  <keyword>Tolerance</keyword>
  <keyword>Cell tolerance</keyword>
  <keyword>Survival</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

